[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"soft-tissue-lesion\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:soft-tissue-lesion":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,72,97],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100504676","galvanize-prospectiveretrospective-pulsed-electric-field-device-registry-100504676",false,"NCT05851430","Galvanize Prospective\u002FRetrospective Pulsed Electric Field Device Registry","PROPEL","Inclusion Criteria:\n\n1. Subject will undergo or has undergone PEF energy delivery utilizing Galvanize technology\n2. Subject is expected to be available for follow-up per the enrolling physician's standard care practices\n3. For prospective cohort, subject has a life expectancy of at least 3 months; for retrospective cohort, subject has completed at least three months of imaging following the PEF procedure\n4. Signed informed consent is obtained, if required by IRB\n\nExclusion Criteria:\n\nNone","ALL","18 Years","100 Years",{"count":20,"type":21},1000,"ESTIMATED","24 Months","OBSERVATIONAL","The goal of this observational registry is to assess the use and performance of Galvanize PEF technology in a real-world setting. The main questions it aims to answer are:\n\n* PEF utilization and performance\n* Monitor safety outcomes and inform future generation devices.\n\nParticipants will undergo the PEF procedure and be followed per institutional standard of care.",[26],"Soft Tissue Lesion",[28],"Pulsed Electric Fields","RECRUITING","2026-07-01",{"date":32,"type":33},"2026-07-02","ACTUAL",{"date":35,"type":33},"2025-06-23",{"date":37,"type":21},"2028-12-31",{"name":39,"class":40},"Galvanize Therapeutics, Inc.","INDUSTRY",11,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":71},"100584852","phase-1-pet-89zrdfo-starpeg-in-solid-tumors-100584852","NCT06894745","PET [89Zr]DFO-starPEG in Solid Tumors","Positron Emission Tomography (PET) Imaging of the Enhanced Permeability and Retention (EPR) Effect With [89Zr]DFO-starPEG in Patients With Solid Tumors","Inclusion Criteria:\n\n1. Age \\>= 18 years.\n2. Histological or cytological confirmation of solid tumor malignancy.\n3. Any malignancy, with at least one soft tissue lesion measurable at 1 centimeter (cm) or greater in short axis measurement on cross sectional imaging such as Computerized tomography (CT), Magnetic resonance imaging (MRI), or Positron Emission Tomography (PET)\u002FCT, OR at least 1 lesion which is positive (defined as greater than surrounding background) in the bones on standard of care cancer imaging PET exam.\n4. Clinically able to undergo PET\u002FCT imaging.\n5. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2 or Karnofsky ≥ 50%.\n6. Adequate organ function as defined below within 0-28 days before \\[89Zr\\]DFO-starPEG administration:\n\n   * Total bilirubin: ≤ 1.5 x institutional upper limit of normal (ULN) (unless elevated due to Gilbert's syndrome and direct bilirubin is within normal limits) .\n   * Aspartate aminotransferase (AST)\u002F serum glutamic-oxaloacetic transaminase (SGOT) ≤ 3 x ULN.\n   * Alanine aminotransferase (ALT)\u002F serum glutamic-pyruvic transaminase (SGPT) ≤ 3 x ULN.\n   * Estimated creatinine clearance: ≥ 60 mL\u002Fmin, calculated using the Cockcroft-Gault equation or 24 hour urine collection.\n7. Females of reproductive potential (defined below) must be willing to undergo a urine or serum pregnancy test (i.e., human chorionic gonadotropin test) within 72 hours before administration of \\[89Zr\\]DFO-starPEG. A female is considered to NOT be of reproductive potential (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice), if they meet either of the following two criteria: (1) has reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause); or (2) has undergone surgical sterilization (i.e., hysterectomy and\u002For bilateral oophorectomy for removal of uterus and\u002For ovaries). The result of the urine or serum pregnancy test must be negative in order to initiate the \\[89Zr\\]DFO-starPEG administration. If a urine pregnancy test cannot be confirmed as negative (e.g., an ambiguous result), a serum pregnancy test is required. In such cases, the individual must be excluded from participation if the serum pregnancy result is positive. Pregnant individuals are excluded from this study because there is an unknown but potential risk for adverse effects in the unborn child secondary to treatment of the study participant with \\[89Zr\\]DFO-starPEG.\n8. Individuals with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or endpoints of this study are eligible.\n9. Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n1. Individuals with a contraindication to PET-CT imaging (e.g., severe claustrophobia).\n2. Individuals who are pregnant or breastfeeding\u002Fchestfeeding. Pregnant and breastfeeding\u002Fchestfeeding individuals are excluded because there is an unknown but potential risk for adverse effects in the unborn\u002Fnursing child secondary to treatment of the study participant with \\[89Zr\\]DFO-starPEG. Females of childbearing potential must have a negative pregnancy test before administration of \\[89Zr\\]DFO-starPEG, as outlined in inclusion criterion #7. Breastfeeding\u002Fchestfeeding should be discontinued before administration of \\[89Zr\\]DFO-starPEG.\n3. Individuals who do not agree to follow the below contraception requirements:\n\n   * Females of reproductive potential (defined below) must agree to use two forms of contraception, consisting of a barrier method (such as condoms) in combination with a secondary complementary method (such as hormonal, intrauterine device (IUD), etc.), or strict abstinence, for the duration of study participation and for 1 month after administration of \\[89Zr\\]DFO-starPEG.\n   * A female is considered to NOT be of reproductive potential (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice), if they meet either of the following two criteria: (1) has reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause); or (2) has undergone surgical sterilization (i.e., hysterectomy and\u002For bilateral oophorectomy for removal of uterus and\u002For ovaries).\n4. Hypersensitivity to \\[89Zr\\]DFO-starPEG or any of its excipients.\n5. Individuals with any condition or social circumstance that, in the opinion of the investigator, would impair the participant's ability to comply with study procedures.",{"count":50,"type":21},13,"INTERVENTIONAL",[53],"PHASE1","This is a first-in-human, pilot study of the novel PET-imaging radiotracer \\[89Zr\\]DFO-starPEG. The study is designed to obtain preliminary data to support future development of this agent as an imaging surrogate to visualize enhanced permeability and retention (EPR)-mediated tracer uptake before administration of EPR-based nanomedicines.",[56,57,26],"Solid Tumor","Solid Carcinoma",[59,60],"Dosimetry","Imaging","2026-06-03",{"date":63,"type":33},"2026-06-05",{"date":65,"type":33},"2025-06-02",{"date":67,"type":21},"2027-12-31",{"name":69,"class":70},"Robert Flavell, MD, PhD","OTHER",1,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":78,"targetDuration":80,"studyType":23,"phases":4,"briefSummary":81,"conditions":82,"keywords":85,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":71},"100629081","prospective-registry-of-histotripsy-for-soft-tissue-tumors-100629081","NCT07470008","Prospective Registry of Histotripsy for Soft Tissue Tumors","Inclusion Criteria:\n\n* All adult patients who are treated with histotripsy per standard clinical care at University of California San Francisco (UCSF) are eligible for inclusion in the registry.\n\nExclusion Criteria:\n\n* Children\u002Fminors, and adults who lack decision-making capacity, will be excluded from the registry. Patients who do not consent for inclusion in the registry will also be excluded.",{"count":79,"type":21},200,"3 Years","Histotripsy is a treatment that uses focused ultrasound waves to break down tissue without surgery. The ultrasound waves meet at a specific spot and turn the tissue into liquid. This study is a prospective observational registry of participants receiving histotripsy. The goal of this study is to gather information about the use of histotripsy to confirm it is safe and effective medical procedure.",[83,84,26],"Soft Tissue Neoplasm","Soft Tissue Cancer",[86,87],"Histotripsy","Ablation","2026-03-13",{"date":90,"type":33},"2026-03-17",{"date":92,"type":33},"2026-01-29",{"date":94,"type":21},"2031-08-08",{"name":96,"class":70},"University of California, San Francisco",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":103,"targetDuration":105,"studyType":23,"phases":4,"briefSummary":106,"conditions":107,"keywords":111,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":71},"100341147","infant-and-child-european-cryoablation-project-icecap-100341147","NCT03721783","Infant and Child European Cryoablation Project ICECaP","Inclusion Criteria:\n\n* all children in whom a clinical decision is made to treat with percutaneous cryoablation, to include those in whom cryoablation was not technically or clinically possible at any stage.\n\nExclusion Criteria:\n\n* none",{"count":104,"type":21},40,"2 Years","A registry to audit the current range of applications, technical success rate, safety profile, complication rate and efficacy of cryoablation procedures being performed in children.",[108,26,109,110],"Therapy","Cryoablation","Pediatric",[112,113,114],"cryoablation","pediatric","registry","2024-10-24",{"date":117,"type":33},"2024-10-26",{"date":119,"type":33},"2021-06-24",{"date":121,"type":21},"2027-07-01",{"name":123,"class":70},"Great Ormond Street Hospital for Children NHS Foundation Trust"]